Kenvue Inc. (KVUE) shares slipped lower Thursday morning without any fresh catalyst, continuing a bruising stretch that's seen the consumer health giant drop roughly 15% over the past six months. For a company that owns household names like Neutrogena, Tylenol, and Listerine, that's not exactly the glow-up investors were hoping for.

The Kimberly-Clark Deal Moves Forward

The big news this month: shareholders gave an overwhelming thumbs-up to Kimberly-Clark Corporation (KMB)'s acquisition of Kenvue. We're talking about 99% approval at Kenvue's Special Meeting, which is the corporate equivalent of a landslide victory. The transaction is expected to close in the second half of 2026, assuming regulators don't throw any curveballs.

The merger represents a significant milestone in building what both companies are calling a global health and wellness powerhouse. Kenvue CEO Kirk Perry has expressed optimism about the growth opportunities that lie ahead for the combined entity, emphasizing the potential for enhanced innovation and expanded market reach for their portfolio of trusted consumer brands.

The rationale is straightforward: combine Kimberly-Clark's operational muscle with Kenvue's brand portfolio to drive innovation and get these products into more hands globally. On paper, it makes sense. Whether the market agrees is another question entirely.

Legal Drama Over Tylenol Safety

Meanwhile, Kenvue continues to navigate some choppy legal waters. Back in November 2025, a Texas judge declined to block a planned shareholder payout despite Texas Attorney General Ken Paxton's efforts to restrict how Kenvue handles and markets Tylenol. The litigation centers on ongoing concerns about the product's safety for pregnant women, a dispute that's been generating headlines for months.

The ruling means Kenvue can proceed with its dividend plans while the broader legal battle grinds on. Not exactly the kind of publicity you want for one of your flagship brands, but at least the cash keeps flowing to shareholders for now.

What the Charts Are Saying

Here's where things get interesting from a technical perspective. Kenvue is currently trading 4.6% above its 20-day simple moving average and 10.7% above its 100-day SMA, which suggests some short-term strength. But zoom out, and the picture darkens: shares have tumbled 11.55% over the past year and are hovering much closer to their 52-week lows than highs.

The technical indicators are sending mixed messages. The RSI sits at 73.07, firmly in overbought territory, which typically signals a potential pullback ahead. At the same time, the MACD is above its signal line, indicating bullish momentum. It's like getting a green light and a yellow light simultaneously, leaving traders to guess which signal matters more.

The combination suggests the stock has had a decent run recently but may be running out of steam. Key resistance sits at $19.00, while support lies around $16.50.

Earnings and What Analysts Think

Kenvue is scheduled to report earnings on February 17, 2026, and expectations are decidedly muted. Analysts are projecting EPS of 22 cents, down from 26 cents a year ago. Revenue is expected to tick up slightly to $3.70 billion from $3.66 billion, so we're talking modest growth at best.

The stock trades at a P/E of 24.7x, which sits in what most would consider fair valuation territory, though not exactly screaming bargain.

Analyst sentiment has cooled noticeably. The consensus rating is Hold with an average price target of $20.18. Recent moves tell the story: Jefferies downgraded to Hold with an $18 target in late January, Barclays maintained Equal-Weight while bumping its target to $18 in November, and Canaccord Genuity dropped the stock to Hold with a $15 target back in October. That's a lot of analyst shrugging, not exactly a confidence builder.

The Bigger Picture

Looking at broader metrics, Kenvue's value score comes in weak at 30.35, indicating the stock is trading at a steep premium relative to peers. Momentum is equally underwhelming with a score of 14.44, showing underperformance against the broader market.

The bottom line? Kenvue finds itself in an awkward spot. The Kimberly-Clark merger offers a compelling long-term narrative about scale and innovation, but the immediate picture involves legal headaches, cautious analysts, and technical signals that suggest the stock might need to catch its breath. With earnings just around the corner, investors have plenty of reasons to stay cautious while the company navigates these company-specific challenges.

KVUE Price Action: Kenvue shares were down 0.32% at $18.48 during premarket trading on Thursday.